Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Press release – No. 1 / 2026

Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44^th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California.

Adam Steensberg, President and Chief Executive Officer, will take part in a presentation and fireside chat on Wednesday January 14 at 1:30pm PST / 10:30pm CET. A live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317741-zealand-pharma/webcast?gpu_only=true&kiosk=true.
A replay of the webcast will be available at https://www.zealandpharma.com/events/.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.  

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: [email protected]

Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: [email protected]

Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
[email protected]

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
[email protected]
+44 (0) 7739 658 783

You May Also Be Interested In

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
• Two-Time Cowboys Super Bowl Champion James Washington Joins Three Wide Brewing Ownership Group
• Anteris to Present at September Healthcare Investor Conferences